Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Minerva Neuroscie (NERV)

Minerva Neuroscie (NERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Minerva Neurosciences: Q1 Earnings Snapshot

Minerva Neurosciences: Q1 Earnings Snapshot

NERV : 2.50 (-0.37%)
Minerva Neurosciences: Q4 Earnings Snapshot

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 2.50 (-0.37%)
Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences: Q3 Earnings Snapshot

NERV : 2.50 (-0.37%)
Minerva Neurosciences: Q2 Earnings Snapshot

Minerva Neurosciences: Q2 Earnings Snapshot

NERV : 2.50 (-0.37%)
Bump up Your Long Term Portfolio Performance With Low Beta Stocks

In this article, discover how low beta stocks can shimmer in your portfolio!

MSFT : 414.89 (+0.62%)
NERV : 2.50 (-0.37%)
STIX : 0.3000 (-19.14%)
SERA : 9.02 (-7.87%)
TCRX : 7.85 (+0.64%)
NVCT : 6.34 (-0.71%)
Minerva Neurosciences: Q1 Earnings Snapshot

Minerva Neurosciences: Q1 Earnings Snapshot

NERV : 2.50 (-0.37%)
Minerva Neurosciences: Q4 Earnings Snapshot

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 2.50 (-0.37%)
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

CANF : 2.10 (-2.01%)
NERV : 2.50 (-0.37%)
AMLX : 1.7706 (-6.32%)
ACER : 0.6601 (-17.95%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

CYBN.NE : 0.4800 (-3.03%)
MRVL.VN : 0.135 (-3.57%)
SAGE : 12.00 (-2.76%)
NERV : 2.50 (-0.37%)
ATAI : 1.92 (-6.34%)
CYBN : 0.3490 (-6.63%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...

MRVL.VN : 0.135 (-3.57%)
SAGE : 12.00 (-2.76%)
NERV : 2.50 (-0.37%)
ATAI : 1.92 (-6.34%)
CYBN : 0.3490 (-6.63%)

Barchart Exclusives

Qualcomm Is Cheap Here Based on Its High FCF Margins - Shorting OTM Puts Is a Good Play
Qualcomm stock looks deeply undervalued here after its recent Q2 results which showed strong free cash flow margins. As a result, one attractive buy-in play is shorting out-of-the-money put options. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar